ABC | Volume 113, Nº1, July 2019

Original Article Kızıltunç et al. Sirtuins in acute myocardial infarction patients Arq Bras Cardiol. 2019; 113(1):33-39 1. Mei Z, Zhang X, Yi J, Huang J, He J, Tao Y. Sirtuins inmetabolism, DNA repair and cancer. J Exp Clin Cancer Res. 2016;35(1):182. 2. Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD- dependent protein lysine demalonylase and desuccinylase. Science. 2011;334(6057):806-9. 3. Mathias RA, Greco TM, ObersteinA, BudayevaHG, Chakrabarti R, Rowland EA, et al. Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell. 2014;159(7):1615-25. 4. Schiedel M, Robaa D, Rumpf T, Sippl W, Jung M. The Current State of NAD(+) -Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets. Med Res Rev. 2018;38(1):147-200. 5. Carafa V, Rotili D, ForgioneM, Cuomo F, Serretiello E, HailuGS, et al. Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics. 2016 May;8:61. 6. Kumar R, Mohan N, Upadhyay AD, Singh AP, Sahu V, Dwivedi S, et al. Identification of serum sirtuins as novel noninvasive protein markers for frailty. Aging Cell. 2014;13(6):975-80. 7. Mariani S, Fiore D, Persichetti A, Basciani S, Lubrano C, Poggiogalle E, et al. Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients. Obes Surg. 2016;26(6):1215-20. 8. Doulamis IP, Tzani AI, Konstantopoulos PS, Samanidis G, Georgiopoulos G, Toutouzas KP, et al. A sirtuin 1/MMP2 prognostic index for myocardial infarction in patients with advanced coronary artery disease. Int J Cardiol. 2017 Mar;230:447-53. 9. Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J. 2015;36(48):3404-12. 10. Sosnowska B, Mazidi M, Penson P, Gluba-Brzozka A, Rysz J, Banach M. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis. 2017 Oct;265:275-82. 11. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESCGuidelines for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST- segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. 12. Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). Am J Cardiol. 2005;95(5):614-8. 13. Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2009;81(3):457-64. 14. Brown AJ, Mccormick LM, Gajendragadkar PR, Hoole SP, West NE. Initial SYNTAX score predicts major adverse cardiac events after primary percutaneous coronary intervention. Angiology. 2014;65(5):408-12 15. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551-67 16. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentationwith acute coronary syndrome: prospectivemultinational observational study (GRACE). BMJ. 2006;333(7578):1091. 17. MorrowDA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286(11):1356-9. 18. Gaziano JM. Global Burden of Cardiovascular Disease. In: Libby P,Bonow RO,Mann DL,Zipes DP (Ed). Braunwald’s Heart Disease, 8 ed. Philedelphi a:Elsevier;2008.p.1-23. 19. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)DevelopedwiththespecialcontributionoftheEuropeanAssociation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016 Sep;252:207-74. 20. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, et al. Endothelium- specificoverexpressionofclassIIIdeacetylaseSIRT1decreasesatherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res. 2008;80(2):191-9. 21. Stein S, Lohmann C, Schäfer N, Hofmann J, Rohrer L, Besler C, et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J. 2010;31(18):2301-9. References Author contributions Conception and design of the research: Kızıltunç E, Kösem A, Çetin M, Ornek E; Acquisition of data: Kızıltunç E, Kösem A, Özkan C, Ilgın BU, Kundi H; Analysis and interpretation of the data: Kızıltunç E, Kösem A, Kundi H, Çetin M, Ornek E; Statistical analysis: Kızıltunç E, Kundi H; Obtaining financing: Kızıltunç E, Özkan C, Ilgın BU; Writing of the manuscript and Critical revision of the manuscript for intellectual content: Kızıltunç E, Kösem A, Özkan C, Ilgın BU, Kundi H, Çetin M, Ornek E. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding This study was funded by Ankara Numune Training and Research Hospital. Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Ankara Numune Training and Research Hospital under the protocol number E-17-1399. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 38